Previous Article | Next Article 
Journal of Virology, August 1999, p. 6387-6393, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Proteolytic Activity, the Carboxy Terminus of Gag, and the Primer
Binding Site Are Not Required for Pol Incorporation into Foamy
Virus Particles
David N.
Baldwin and
Maxine L.
Linial*
Division of Basic Sciences, Fred Hutchinson
Cancer Research Center, Seattle, Washington 98109, and Department of
Microbiology, University of Washington, Seattle, Washington 98195
Received 3 March 1999/Accepted 4 May 1999
 |
ABSTRACT |
Human foamy virus (HFV) is the prototype member of the
spumaviruses. While similar in genomic organization to other complex retroviruses, foamy viruses share several features with their more
distant relatives, the hepadnaviruses such as human hepatitis B virus
(HBV). Both HFV and HBV express their Pol proteins independently from
the structural proteins. However unlike HBV, Pol is not required for
assembly of HFV core particles or for packaging of viral RNA. These
results suggest that the assembly of Pol into HFV particles must occur
by a mechanism different from those used by retroviruses and
hepadnaviruses. We have examined possible mechanisms for HFV Pol
incorporation, including the role of proteolysis in assembly of Pol and
the role of initiation of reverse transcription. We have found that
proteolytic activity is not required for Pol incorporation. p4 Gag and
the residues immediately upstream of the cleavage site in Gag are also
not important. Deletion of the primer binding site had no effect on
assembly, ruling out early steps of reverse transcription in the
process of Pol incorporation.
 |
INTRODUCTION |
Human foamy virus (HFV) is the
best-characterized member of the Spumavirus genus of the
family Retroviridae (33). Foamy viruses are
complex retroviruses, encoding the canonical retroviral genes
gag, pol, and env, as well as several
accessory genes (13). Despite clear sequence and genomic
structural homology with other retroviruses, several features of HFV
replication are similar to more distant relatives, the hepadnaviruses,
which are the only other mammalian reverse transcriptase (RT)-encoding
viruses (1, 40).
Like hepatitis B virus (HBV), HFV expresses its Pol protein
independently of structural proteins (11, 27, 40). Foamy viruses express Pol from a spliced mRNA, whereas hepadnaviruses use
either ribosomal scanning or internal initiation (20). The resulting HFV Pol polyprotein contains no Gag domains and must therefore be assembled into particles by a mechanism different from
those used by other known retroviruses, where Gag-Pol fusion proteins
are incorporated into particles via Gag-Gag interactions (14, 21,
35). We have previously demonstrated that the requirement for HFV
Pol during assembly is similar to what has been found for other
retroviruses and different from that found for hepadnaviruses. As with
other retroviruses, abrogation of HFV Pol expression has no effect on
assembly of particles, packaging of viral genomic RNA, or release of
virus from the cell (1). For hepadnaviruses however, the P
protein is required to initiate proper assembly and is essential for
genome encapsidation (3, 5, 31, 32). While these data
suggest an HFV assembly pathway which is initiated as in other
retroviruses, they give no hint of how the Pol protein might be
incorporated into the particles.
The pathway of HFV reverse transcription also follows the retroviral
paradigm in which the initiation at the primer binding site (PBS)
requires complex formation with a specific tRNA. The HFV PBS contains
18 nucleotides of perfect homology to the 3' end of both rat and human
tRNA1,2Lys, and there is evidence for synthesis of
strong-stop DNA (23, 24). In contrast, the HBV P protein
binds in cis to a secondary structure (
) in the genomic
RNA (3, 5, 31, 32), an event which initiates both reverse
transcription and assembly, processes which are intimately coupled
(32). Priming of HBV reverse transcription uses a tyrosine
residue on the N-terminal domain of the P protein (37). A
HFV Pol deletion mutant still packages RNA (1),
demonstrating a clear difference from the assembly pathway of HBV.
The activities of the HFV Pol domains have been studied in vitro. The
RT activity from a foamy virus was first demonstrated in 1971 (29), and later template-primer sets for endogenous RT
activity were optimized for simian foamy virus 1 (7), and the foamy virus "strain H4188" (26). The HFV RT domain
has been expressed in Escherichia coli and shown to have DNA
polymerase activity in in situ RT gel assays (23, 24). The
RNase H (RH) domain has also been shown to be active (6,
23). An unusual feature of HFV is that Pol is activated before or
during viral assembly and release. About 25% of HFV particles contain
full-length DNA (40, 42), and experiments with RT inhibitors
such as zidovudine are consistent with the fact that DNA is the
infectious genome (28, 40). It is unclear exactly when
reverse transcription begins. The finding that the RNA genome is
packaged by Gag (1) does not rule out the possibility that
reverse transcription is initiated early in assembly. Therefore, it is
also possible that complex formation between Pol, tRNA, and the PBS is
required for packaging Pol protein into virions.
Although HFV Pol contains a protease (PR) domain, the proteolytic
processing of Gag and Pol by the HFV PR is different from that in other
retroviruses. Only two cleavage events are known to occur
(25). The 78-kDa HFV Gag protein is processed once at its C
terminus, to release a 4-kDa peptide, an event which occurs in
approximately 50% of the Gag precursor molecules. Recent work suggests
that this cleavage is required for efficient replication, since mutants
which lack cleavage site replicate less well and revert to wild type in
culture. Mutants lacking the C-terminal p4 protein can also replicate,
but at very low levels (10). The exact Gag cleavage site has
been identified biochemically by using recombinant PR (30).
PR also cleaves the 127-kDa Pol polyprotein once to release a 45-kDa
integrase protein (IN), but the exact site of cleavage between the
reverse transcriptase (RT/RH) and IN remains unknown. This cleavage is
probably essential, as a PR active site mutant (HFV-D/A) is not
replication competent (25). There are no data bearing on the
role of proteolytic processing for packaging of Pol proteins into virions.
In this report, we investigate the role of proteolytic cleavage,
complex formation of RT at the PBS, and initiation of reverse transcription with respect to their importance for the incorporation of
the Pol protein into particles. We demonstrate that neither PR activity
nor the PBS is required for Pol assembly.
 |
MATERIALS AND METHODS |
Recombinant plasmid DNAs.
A shuttle vector was generated to
facilitate cloning and manipulation of five unique restriction-derived
fragments from the original molecular clone of HFV, human
spumaretrovirus clone 13 (HSRV13) (33). An annealed set of
kinase-treated linker oligonucleotides was added to the NEB193 (New
England Biolabs) polylinker at the PacI site to generate
plasmid HFVLink2 (L2). The insertion destroyed the existing
PacI site. These oligonucleotides were Linktop
(5'-CGGCCGATTTAAATTAATTAATCCGGAGCTGAGCTTAAGCCTAGGGATATCATGCATAT-3') and Linkbot
(5'-ATGCAT GATATCCCTAGGCTTAAGCTCAGCTCCGGATTAATTAATTTAAATCG GCCGAT-3').
This insert contains all of the unique sites from the viral sequence of
HSRV13. The insert was screened for orientation such that the enzyme
sites were in the following order with respect to the NEB193
polylinker: BamHI (NEB193), EagI,
SwaI, PacI, BspEI, BlpI,
AflII, AvrII, EcoRV, NsiI,
XbaI (NEB193), SalI (NEB193).
Five unique fragments of the HFV genome from HSRV13 were then cloned
into the L2 vector. Each subclone was named according to the position
of the unique fragment in the genome. Sub1 contains EagI-SwaI, Sub2 contains
SwaI-PacI, Sub3 contains
PacI-BspEI, Sub4 contains
BspEI-BlpI, and Sub5 contains
BlpI-SalI. These subclones were subsequently used
for PCR mutagenesis.
PCR mutagenesis.
The general strategy for mutagenesis was as
follows. Two oligonucleotides corresponding to sequences outside the
NEB193 polylinker were used in all mutagenesis reactions. The external
primers were 193(+), corresponding to positions 21 to 40 in NEB193
(5'-GGTGAAACCTCTGACACAT-3'), and 193(
), corresponding to
positions 577 to 558 (5'-CCCAGGCTTTACACTTTATG-3'). Internal
primers were designed to contain mutations and a unique NheI
site for ligation of PCR products. Ligated PCR products were digested
with enzymes unique to the L2 polylinker and subcloned into L2.
A protein kinase A (PKA) phosphorylation site was introduced in the C
terminus of the IN domain of Pol. The consensus PKA
sequence is
Arg-Arg-X-Ser-X (RRxSx), where x is preferably a small
hydrophobic
amino acid (
4,
5,
38). Nucleotide positions
6262 to 6265 were changed from ATT to CGT, converting isoleucine
to arginine.
Positions 6269 to 6275 were changed from ACTTCT to
GCTAGC, converting a threonine to alanine such that the
amino
acid sequence IRTSL was changed to RRASL. The oligonucleotides
for PCR were Nhe1top
(5'-TTACAGGAACGTCGTGCTAGCTTATACCATCCATCCACCCCTCCAGCC-3')
with 193(

) and Nhe1bot
(5'-ATGGTATAAGCTAGCACGACGTTCCTGTAAAAGAGAAAGTTCTTCTTC-3')
with 193(+); 5 ng of Sub3 was used as a template for PCR. PCR
products were digested with
NheI and ligated to each other.
The
ligation product was digested with
BamHI and
SalI and subsequently
cloned into
BamHI/
SalI-digested L2 vector. The
PacI/
BspEI fragment
containing the PKA (Sub3-PKA)
site was then cloned back into HSRV13
and named HFV-PKA. The same
PacI/
BspEI fragment was then cloned
into
different mutant
backgrounds.
The PR active site mutant HFV-D/A contains an aspartic acid-to-alanine
mutation at the active site of the viral PR (
25).
Sub3-PKA
was cloned into the D/A background as described above
and named
HFV-D/A-PKA. The negative control for assembly,

ATG
was generated by
digesting the Sub1 vector with
MfeI and
NcoI,
filling in with Klenow, and religating. This was then transferred
to
the PKA and the D/A-PKA backgrounds, which were called

ATG-PKA
and

ATG-D/A-PKA, respectively. Three Gag mutants were constructed
in a
similar fashion, using the Sub2 vector; these are called
78T/A, 74Stop,
and 68Stop. For each mutant, two separate PCRs
were performed with
mutagenic oligonucleotides and the vector-based
oligonucleotides 193(+)
and 193(

). Both PCR products contained
an
NheI site in the
region downstream of the desired mutation
in Gag. PCR products were
digested with
NheI, ligated together,
and redigested with
enzymes unique to the polylinker flanking
the HSRV13 unique sites. The
Sub2 mutants were then cloned back
into the viral background with the
enzymes
SwaI and
PacI. The
oligonucleotides used
for these reactions were 78T/A-1
(5'-AGCCTTGCTAGCCAGAGTGCCACGTCCTCCACAGATC-3'),
78T/A-2
(5'-CAGTTCGCTAGCTGCGGCGACAGCGCGTGAGTCACCAGC-3'), 74STOP-2
(5'-GTACGCTAGCTTACTAATTGACAGCGCGTGAGTCACCAGC-3'), 68STOP-1
(5'-AGCCTTGCTAGCCGCGGAGGAAGAGGTAACCACAACCG-3'),
and 68STOP-2
(5'-GTACGCTAGCTTACTAAGCTGGTCTGGGAGTTTGTGACTG-3').
Primer
pairs were as follows for the initial reactions: 78T/A,
193(+) plus
78T/A-2 and 193(

) plus 78T/A-1; 74STOP, 193(+) plus
78T/A-2 and
193(

) plus 74STOP-1); 68STOP, 193(+) plus and 68STOP-2
and 193(

)
and 68STOP-1. For the STOP mutants, the coding sequence
was unaltered
prior to the TAA insertion. The cleavage site mutant
78T/A contains
four mutations at and near the cleavage site, changing
the amino acid
sequence from NTVT to AAAS. The amino acids alanine
and serine (AS)
correspond to the coding sequence of the
NheI
site
(GCTAGC) used to ligate the PCR products. These mutants were
generated twice, once in the wild-type HFV-PKA [HFV (wt)] background
and once in the D/A-PKA
background.
The PBS was deleted from Sub1 and subsequently recloned into various
viral backgrounds. The PBS sequence (5'-TGGCGCCCAACGTGGGG-3';
positions 1124 to 1142 of the proviral DNA) was replaced with
an
NheI site (AGCGCT) by the PCR strategy described
above. The
oligonucleotides used for the PBS deletion were PBS-NHE-1
(5'-AGTGATGCTAGCCTCGAATATAAGTCGGGTTTATTTG-3')
and PBS-NHE-2
(5'-TCAGATGCTAGCATTGTCATGGAATTTTGTATATTG-3'). Primer
sets
were 193(+) plus PBS-NHE-2 and 193(

) plus PBS-NHE-1.
Cell culture and transient transfection.
FAB indicator cells
expressing
-galactosidase from the HFV long terminal repeat were
maintained in Dulbecco's modified Eagle's medium supplemented with
5% fetal bovine serum. Transfection and infection efficiencies were
measured directly with FAB cells by fixing and staining with a
colorometric substrate for
-galactosidase (41). FAB cells
stain blue only when the HFV transactivator Tas (present in all
proviral constructs) is expressed. Human embryonic lung fibroblasts,
COS cells, and 293T cells were maintained in Dulbecco's modified
Eagle's medium-10% fetal bovine serum. Transfections were performed
with Lipofectamine reagent (Gibco-BRL) according to the manufacturers
instructions and optimized for our cells and DNA as previously
described (1).
Gradient purification of HFV particles.
Transfected cell
supernatants were clarified of cell debris by low-speed centrifugation
(2,000 rpm; IEC clinical HN-SII tabletop centrifuge) and filtered
through a Nalgene 0.45 µm-pore-size syringe filter. Virus was
pelleted through standard buffer (50 mM Tris [pH 7.5], 1 mM EDTA, 140 mM NaCl) containing 20% sucrose by ultracentrifugation in an SW28
rotor (Beckman Instruments) at 24,000 rpm for 2 h. Virus was
resuspended in standard buffer and placed on a 10 to 40% step gradient
of iodixanol (Optiprep; Nycomed Pharma). The 5-ml gradients were formed
by sequentially underlaying 1-ml aliquots of increasing concentrations
of iodixanol at 10, 20, 30, and 40%. Gradients were centrifuged from 4 to 12 h at 36,000 rpm in a Ti55 rotor (Beckman Instruments).
Gradients were made in 5-ml Beckman Ultraclear tubes (13 by 51 mm);
0.7-ml fractions were collected from the top of the gradient, and
proteins were precipitated from each by adding trichloroacetic acid
(TCA) to a final concentration of 10%. The precipitates were pelleted
at 14,000 rpm in a microcentrifuge (Eppendorf), washed once with 10%
TCA to remove the iodixanol, and finally washed with acetone to remove
the TCA. Pellets were resuspended in Tris-EDTA (TE) containing 1%
sodium dodecyl sulfate (SDS) and boiled to solubilize the precipitate;
10% of each fraction was then analyzed by Western blotting for viral
Gag protein, using polyclonal anti-Gag antibody derived from the
central (capsid) domain of Gag (1), and the remaining 90%
was diluted 1:10 in TE (pH 8.0) (0.1%, final concentration) for
immunoprecipitation (IP)-PKA analysis of the Pol proteins (see below).
Protein kinase assay for detection of Pol.
The catalytic
subunit of PKA (Sigma) was used to phosphorylate viral and cellular Pol
proteins containing the recognition sequence RRxSx (4, 5,
38). For all figures in this report, Pol proteins were
immunoprecipitated from cell lysates or viral pellets by using
polyclonal anti-RH rabbit serum (1). Pol expression was also
verified by two independent criteria. The same Pol proteins were
detected by IP-kinase reactions using either anti-IN serum (Martin
Löchelt, Heidelberg, Germany) or anti-RH serum. In addition, radioimmunoprecipitation with the anti-RH serum as previously described
(1) (data not shown) verified that the 127-kDa band seen in
the IP-kinase assays was in fact the Pol protein. Cellular Pol protein
was immunoprecipitated from one transfected plate of FAB cells. Lysates
for IP were prepared by resuspending cells or virus in antibody buffer
(20 mM Tris [pH 7.5], 50 mM NaCl, 0.5% Nonidet P-40 [NP-40], 0.5%
SDS, 0.5% sodium deoxycholate [DOC], 0.5% aprotinin), cellular
nucleic acids were sheared with a 23-gauge needle, and insoluble
materials were pelleted and discarded; 2 to 4 µl of antiserum was
added to the lysate and vortexed. The immune complexes were
precipitated with protein A-Sepharose for 3 h at 10°C, washed
twice with high-stringency radioimmunoprecipitation assay (RIPA) buffer
(10 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 1% DOC, 0.1% SDS,
0.5% aprotinin), washed once with high-salt buffer (10 mM Tris [pH
7.4], 2 M NaCl, 1% NP-40, 1% DOC), and finally washed with 1× PKA
buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 12 mM MgCl2, 4 mM dithiothreitol). PKA was added in 1× PKA buffer (20 U/reaction) in
the presence of 10 to 25 µCi of [
-32P or
33P]ATP. Reactions were carried out at 37°C for 30 to 60 min. The complex was then washed twice with RIPA buffer to remove most of the unincorporated label. A second IP was performed by boiling the
complex in TE-1% SDS, removing the supernatant, and diluting it 1:10
in TE (pH 8.0). Fresh anti-Pol antiserum and protein A-Sepharose were
added for 3 h. This complex was again washed three times with RIPA
buffer and once with TE. Then 1× SDS-polyacrylamide gel
electrophoresis (PAGE) sample buffer was added directly, and the
samples were boiled for 5 to 10 min. Proteins were separated by
SDS-PAGE, dried onto Whatman 3MM, and exposed to film or a PhosphorImager screen.
 |
RESULTS |
Proteolytic processing of Gag or Pol is not required for assembly
of Pol into HFV particles.
To better understand the role of the
viral PR during assembly, we wanted to test whether the HFV PR active
site mutant (HFV-D/A) was capable of assembling Pol into virions.
However there are inherent difficulties in detecting the small amount
of Pol protein present in virions from transiently transfected cells.
Since traditional methods such as Western blot analysis and
radioimmunoprecipitation analysis failed to convincingly detect Pol, we
introduced a consensus recognition sequence for the catalytic subunit
of PKA (HFV-PKA) into the pol gene. This method had
previously been used to detect the HBV P protein (4, 5). The
PKA site was introduced near the C terminus of IN via site-directed PCR
mutagenesis, by changing the amino acid sequence IRTSL to RRASL (Fig.
1A). Using antibodies raised against the
RH domain of Pol, we were able to immunoprecipitate and specifically
phosphorylate the 127-kDa Pol precursor from transfected cells (Fig.
1B, lane 3; Fig. 1C, lane 1). Although we used anti-RH serum, we also
detected the cleaved form of IN (45 kDa) by SDS-PAGE. This suggests
that either cleavage can occur in vitro after IP or that the complex
between the cleaved Pol proteins is stable under the conditions used
for the IP. Interactions between RT and IN have been demonstrated for
other retroviral Pol proteins (19, 39). In the wild-type
HFV-transfected cells (Fig. 1B, lane 2), no specific bands were seen,
indicating that phosphorylation of Pol requires the engineered PKA
site. Analysis of the Gag proteins demonstrated that cleavage of Gag by
the HFV-PKA Pol is similar to that seen for HFV (wt) (Fig. 1D, lanes 1 and 2). While the expression and processing of Gag and Pol appear normal for HFV-PKA, infectivity was reduced 1,000-fold with respect to
HFV (wt) (data not shown). We presume but have not established that
this difference is due to a defect in integration. Since all of our
analyses are done during the first round of replication, before
reinfection can occur, the integration status is not important.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
IP-PKA and Western blot analysis of HFV-PKA and
HFV-D/A-PKA. Assay conditions are as described in Materials and Methods
except that the second IP step was omitted for PKA analysis of cellular
Pol proteins. Anti-RH antiserum was used to immunoprecipitate Pol, and
anticapsid antiserum was used for Gag Western blots. (A) Schematic
diagram of HFV (wt) and HFV-PKA Pol proteins. (B) IP-PKA analysis of
HFV-PKA. Lanes: 1, positive control for PKA phosphorylation; purified
interleukin-1 receptor (38); 2, HFV (wt)-transfected cells;
3, HFV-PKA-transfected cells. (C) PKA analysis of cell lysates mock
transfected (lane 3) or transfected with HFV-PKA and HFV-D/A-PKA (lanes
1 and 2, respectively). (D) Western blot analysis of HFV-PKA Gag
proteins. Lanes: 1, HFV (wt); 2, HFV-PKA; 3, HFV-D/A-PKA.
|
|
We next subcloned the PKA mutation into the PR active site mutant
background, HFV-D/A, in order to study the role of proteolysis
during
assembly. As expected for HFV-D/A-PKA, we no longer detected
cleavage
of either Pol (by the IP-kinase assay [Fig.
1C, lane
2]) or Gag (by
Western blot analysis [Fig.
1D, lane 3]). As a
negative control for
virus assembly, we constructed a mutant with
a deletion spanning the
initiation codon for Gag. This mutant,

ATG-D/A-PKA (Fig.
2A), contains a deletion of 1,240 bases
beginning
at position 1120 of the proviral sequence and ending at
position
2368, upstream of the 3' splice site for
pol.

ATG-D/A-PKA makes
no detectable Gag by Western blot analysis (Fig.
3C, lane 1) but
regularly expresses Pol at higher levels than
Gag-expressing proviral
constructs such as HFV-D/A-PKA (Fig.
2B, lanes
1 and 2) when transfection
efficiencies are comparable as measured by

-galactosidase activity
in FAB cells.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Optiprep gradient purification and analysis of Gag and
Pol proteins from HFV-D/A-PKA virus particles. Gradients and analyses
were performed as described in Materials and Methods. (A) Schematic of
negative control for virus assembly and Pol incorporation, ATG-PKA.
(B) IP-PKA analysis of cell-associated Pol proteins from ATG-PKA and
HFV-D/A-PKA, using anti-RH serum. Cells were transfected with
ATG-D/A-PKA (lane 1) or HFV-D/A-PKA (lane 2) or mock transfected
(lane 3). (C) Western blot analysis of purified HFV-D/A-PKA particles,
using anti-Gag antiserum. Fraction densities (in grams per cubic
centimeter) are listed above the lanes. Lanes 1 to 7 correspond to
fractions 1 to 7 from the gradient; 78 kDa is the expected size for
unprocessed Gag from HFV-D/A-expressing constructs (Fig. 3A). (D)
IP-PKA analysis of gradient-purified HFV-D/A-PKA virus particles. Lanes
1 to 4 correspond to fractions 3 to 6 from the gradient. Fraction
densities (in grams per cubic centimeter) are listed above the lanes.
(E) IP-PKA analysis of gradient fractions from cell supernatants of the
negative control for virus assembly, ATG-D/A-PKA. Lanes 1 to 4 correspond to fractions 3 to 6.
|
|
We then purified HFV-D/A-PKA virus particles of the correct density
from cell supernatants to determine whether Pol is encapsidated.
To
this end, viral pellets were resuspended and centrifuged to
density
equilibrium on gradients of iodixanol (Optiprep). Iodixanol
gradients
have previously been used to study the incorporation
of Vif into human
immunodeficiency virus type 1 virions (
9).
We found that
HFV-D/A-PKA particles sedimented at the appropriate
density of 1.12 to
1.15 g/cm
3 (Fig.
2C, lanes 4 and 5) as detected by Gag
Western blot analysis
of the gradient fractions. When we analyzed the
same fractions
for the presence of Pol, we were able to detect
HFV-D/A-PKA Pol
cosedimenting with Gag (Fig.
2D, lane 2). Importantly,
extracellular
Pol was not detected in gradient fractions of comparable
density
from cells expressing Pol but no Gag (Fig.
2E). Thus, we
conclude
that detection of Pol in fractions at 1.12 to 1.15 g/cm
3 requires particle formation. Taken together, these
data indicate
that proteolytic activity is not necessary for the
specific incorporation
of HFV Pol into
virions.
The primary structure at the cleavage site in Gag is not important
for Pol incorporation into particles.
We were interested in
determining whether the binding event which initiates the single
cleavage of Gag by PR might be responsible for recruiting Pol into
particles. We tested several mutations at or near the cleavage site
(Fig. 3A). The Gag cleavage site was
mutated to block cleavage (78T/A); two Gag truncation mutants, 74Stop
(truncated exactly at the cleavage site) and 68Stop (truncated 25 amino
acid residues upstream of the cleavage site) were also generated. We
introduced these mutations into the HFV-PKA (wtPR) background. We found
that Gag proteins of the expected sizes were expressed by all of these
clones after transfection (Fig. 3B, lanes 3 to 5).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of cellular Gag and Pol expression from HFV-PKA
and HFV-D/A-PKA mutants. (A) Schematic of expected Gag protein products
from mutant proviral constructs. (B) Western blot analysis of Gag
proteins from cells mock transfected (lane 6) or transfected with the
constructs indicated at the top. (C) Western blot analysis of Gag
proteins from cells mock transfected (lane 7) or transfected with the
HFV-D/A-PKA-expressing constructs indicated at the top. (D) IP-PKA
analysis of cellular Pol proteins. Shown are the mutants in the
D/A-PKA background which were tested for Pol incorporation into
virus particles. These experiments included a second IP step after the
phosphorylation reaction.
|
|
Detection and quantitation of HFV-PKA Pol in virions proved difficult
due to HFV PR activity either before or during the IP-kinase
assay.
Although the signal-to-noise ratio was greatly improved
by the use of a
second IP after the IP-kinase reaction, cleaved
forms of IN might be
lost during the second IP, preventing quantitative
comparison of the
Gag mutants to the PR active site mutant. As
PR activity was not
required for Pol incorporation, the same Gag
mutations were generated
in the D/A-PKA background. When the resultant
mutant viruses were
analyzed by Western blotting, Gag proteins
of the correct size were
detected (Fig.
3C, lanes 4 to 6). No
Gag was synthesized by the Gag
deletion mutant,

ATG-D/A-PKA (Fig.
3C, lane 1). In the IP-kinase
assay, Pol proteins were expressed
at similar levels in cell extracts
after transfection with the
Gag mutant constructs (Fig.
3D, lanes 2 to
4).
Virus particles produced after transfection with the Gag mutants were
purified on iodixanol gradients and probed for Gag by
Western blotting
(Fig.
4A, lanes 4 and 5). All of the
mutants
analyzed sedimented at a density similar to that of the D/A-PKA
parental virus (Fig.
2B). When the corresponding fractions were
analyzed for Pol, we were able to detect Pol in each of the Gag
mutants
(Fig.
4B, lanes 1 and 2). No Pol could be detected in
other fractions
of the gradient (data not shown). These results
demonstrate that while
the cleavage of Gag seems to be an important
step in the replication
cycle of HFV (
10), neither the Gag cleavage
site itself nor
the primary sequence immediately surrounding it
is required for
incorporation of Pol into virus particles.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 4.
Gradient purification and analysis of Gag mutant
viruses. (A) Western blot analysis of gradient fractions for viral Gag.
Lanes 1 to 7 correspond to gradient fractions 1 to 7. (B) IP-PKA
analysis of fractions 4 to 6 from the gradients shown in panel A. Lanes
1 to 3 correspond to fractions 4 to 6. 78A, 78T/A; 74S, 74Stop; 68S,
68Stop (see Fig. 3B for schematic). Fraction densities (in grams per
cubic centimeter) are listed above the lanes.
|
|
The PBS is not essential for Pol incorporation.
Binding of Pol
to the PBS occurs at an early stage of HFV assembly, and it is possible
that this step is responsible for its incorporation into particles.
Such a scenario would be similar to what is found for HBV, where P
protein binds to
and initiates both reverse transcription and
assembly (3, 5, 31, 32). Since HFV Pol is active during
assembly, rather than at an early stage after infection, the mechanism
of HFV Pol assembly could involve a specific stage of reverse
transcription. We deleted the PBS by PCR mutagenesis (Fig.
5A). In the
PBS constructs, Gag was
expressed as expected. Gag was processed in the HFV-PKA background
(Fig. 3B, lane 2) and not processed in the D/A-PKA background (Fig. 3C,
lane 3).
PBS-D/A-PKA Pol was expressed in transfected cells at
levels similar to those of other D/A-PKA-expressing mutants (Fig. 3D,
lane 1). Gradient-purified particles from the
PBS-D/A-PKA-transfected cells sedimented at 1.12 to 1.15 g/cm3, as seen for other mutant viruses (Fig. 5B, lanes 4 and 5), and Pol was detected in the same fractions (Fig. 5C, lanes 2 and 3), demonstrating that Pol was indeed present in these particles. Thus, the PBS is not required for Pol assembly.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Gradient purification and analysis of PBS-D/A-PKA.
(A) Detailed schematic of the PBS deletion on the RNA genome. Shown is
the homology with the 3' end of tRNA1,2Lys from which
reverse transcription is initiated. Deleted nucleotides are underlined;
a putative 5' encapsidation signal is labeled . (B) Western blot
analysis of Gag. Lanes 1 to 7 correspond to fractions 1 to 7. Fraction
densities (in grams per cubic centimeter) are listed above the lanes.
(C) IP-PKA analysis of Pol proteins. Lanes 1 to 4 correspond to
fractions 3 to 6 shown in panel B.
|
|
 |
DISCUSSION |
During the course of these studies on the mechanisms of Pol
expression and assembly, we noticed that HFV Pol expression is quite
low, both at the mRNA level (40) and at the protein level (1, 2). We were unable to detect Pol in virus particles without radiolabeling in vitro. The regulation of Gag and Pol stoichiometry is an important aspect of retroviral replication. Conventional retroviruses have evolved sophisticated mechanisms to
regulate both Pol expression and activation (reviewed in references 8 and 21). Synthesis of Pol as a
Gag-Pol fusion protein keeps the level of Pol protein low, allows
incorporation of Pol into particles via Gag domains, and prevents
activation of Pol until a subsequent round of infection. It could be
detrimental to the host cell to have active RT in the cytoplasm
where mRNA substrates are abundant. In the case of conventional
retroviruses, overexpression of Gag-Pol and the resulting
activation of PR in the cytoplasm has been shown to negatively affect
virus assembly (22). While on average, retroviruses contain
two copies of their genomic RNA per virion, they contain one Gag-Pol
fusion for every 20 Gag molecules (21), or about 100 Pol
proteins per virion (36). Hepadnaviruses have a much lower
ratio of P protein to core protein per virion. Since P binds to the
signal in the RNA, there are only one or two P proteins per virion
(5). It is not known how many Pol molecules there are per
HFV particle. If Pol-RNA interactions are required, then the ratio of
Pol to Gag in virions could be as low as one to two Pol proteins per
virion, which is consistent with difficulty in detecting Pol in
particles. However, even if Gag-Pol interactions are responsible for
assembly, low levels of Pol synthesis could be the limiting factor.
Quantitative analyses of the ratio of Gag and Pol in cells and
particles have not yet been done.
The mechanisms for regulation of expression and activation of HFV Pol
are not known. Splicing to generate pol mRNA is one step
where regulation could occur (11, 27, 40). Translation of
the spliced mRNA may also be regulated, as the pol gene
contains a very long 5' untranslated region. We were unable to get Pol expression from cytomegalovirus promoter constructs lacking the bona
fide splice junction (data not shown), consistent with a role for the
untranslated region in protein expression. It has recently been shown
for HBV that the dicistronic message which results in P protein
expression is regulated at the translational level (20). The
ATG mutant, however, leads to higher levels of Pol expression than
Gag-expressing proviruses (Fig. 2C; compare lanes 1 and 2). Perhaps for
the
ATG mutant, Pol can be translated from both spliced and
unspliced mRNAs, whereas for wild-type HFV, gag translation
downmodulates pol expression during viral replication. Another outstanding question is how Pol is activated. Our data suggest
(Fig. 1 and 2) that PR activity is not important for Pol incorporation,
but how are the activities of PR and RT temporally controlled? It is
likely that cleavage of Pol plays a role in activation, a step which
appears to be initiated after Pol incorporation. This is the case for
other retroviruses where RT activity is dependent on cleavage by PR
during virion maturation. For avian leukosis virus, Gag-Pol precursors
have very little RT activity until processed by PR in trans
after assembly and during maturation (34). While the
mechanisms regulating retroviral maturation remain a mystery, the
regulation of RT activation is clearly an important issue to both the
virus and its host. Perhaps a molecular chaperone, such as one of the
Hsp family members, sequesters the HFV Pol protein until it can find
its binding partners. In the case of HBV RT, the chaperone Hsp90 binds
to and is essential for the activity of the enzyme during assembly
(16-18).
In this study, we examined the mechanism of Pol assembly in HFV. We
have considered both Pol-protein and Pol-RNA interactions, as well as
the role of proteolysis. We have found that neither the activity of the
viral PR nor the PBS is required for assembly of Pol into particles.
Our studies to date, therefore, do not answer the question of whether
Pol incorporation occurs through protein-protein or protein-RNA
interactions. If protein-protein interactions are important, the PR
domain remains a likely candidate. Delineation of a region in Gag
critical for Pol incorporation is an important next step.
If Pol-RNA interactions are important, the region of the aHFV genome
located at the 3' end of the pol gene, which has been reported to be critical for HFV vector transfer (12, 15), is
a good candidate. While the role that this genome region plays in
vector transfer is not known, it might contain sequence information or
secondary structure which directs Pol binding. If the pol
region of the genome is important for Pol assembly, the spliced
pol mRNA might interfere, but this mRNA should not be
packaged since it does not contain the putative
region required for
vector transfer. Alternatively, the presence of ribosomes on the
pol message might block the ability of the RNA to form the
appropriate secondary structure for Pol recognition. Additionally,
posttranslational translocation of Pol protein would also be required.
Pol proteins would then have a much higher probability of encountering
the abundant viral genome than the spliced pol message in
the cytoplasm. If Pol-RNA interactions are important for assembly, then
genome dimerization could also play a role in secondary structure
formation and hence Pol assembly. Dimerization of Pol proteins and
viral genomes might even act in concert to assemble Pol and RNA. It is
also possible that Env plays a role in the assembly of Pol since
Gag-Env interactions are required for very late stages of assembly
(1).
While these studies do not reveal the actual mechanism of Pol assembly,
they have ruled out two essential processes in the replication pathway.
In the future, it will be important to study domains of Gag and Pol and
to look at the effects of uncoupling RNA packaging and Pol
incorporation in Gag mutants. Delineation of a mechanism could come
from Gag mutants lacking only one of these functions.
 |
ACKNOWLEDGMENTS |
D.N.B. was supported by Public Health Service National Research
Service Award T32 GM07270 from the National Institute of General Medical Sciences. This investigation was also supported by grant CA18282 from the National Cancer Institute to M.L.L.
We thank Christopher Meiering for thoughtful discussions and help with
the design and implementation of subcloning and mutagenesis strategies.
We thank Michael Emerman (FHCRC) for valuable discussion and critical
reading of the manuscript, Markus Karl Dettenhofer (Johns Hopkins
University, Baltimore, Md.) for input regarding the Optiprep reagents,
and Martin Löchelt and Rolf Flügel (Heidelberg, Germany)
for kindly providing IN antiserum.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Basic Sciences, Fred Hutchinson Cancer Research Center, A3-015, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA 98109-1024. Phone: (206) 667-4442. Fax: (206) 667-5939. E-mail: mlinial{at}fhcrc.org.
 |
REFERENCES |
| 1.
|
Baldwin, D. N., and M. L. Linial.
1998.
The roles of Pol and Env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 2.
| Baldwin, D. N., and M. L. Linial. 1998. Unpublished results.
|
| 3.
|
Bartenschlager, R.,
M. Junker-Niepmann, and H. Schaller.
1990.
The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation.
J. Virol.
64:5324-5332[Abstract/Free Full Text].
|
| 4.
|
Bartenschlager, R.,
C. Kuhn, and H. Schaller.
1992.
Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites.
Nucleic Acids Res.
20:195-202[Abstract/Free Full Text].
|
| 5.
|
Bartenschlager, R., and H. Schaller.
1992.
Hepadnavirus assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome.
EMBO J.
11:3413-3420[Medline].
|
| 6.
|
Benzair, A. B.,
A. Rhodes-Feuillette,
R. Emanoil-Ravicovitch, and J. Peries.
1983.
Characterization of RNase H activity associated with reverse transcriptase in simian foamy virus type 1.
J. Virol.
47:249-252[Abstract/Free Full Text].
|
| 7.
|
Benzair, A. B.,
A. Rhodes-Feuillette,
R. Emanoil-Ravicovitch, and J. Peries.
1982.
Reverse transcriptase from simian foamy virus serotype 1: purification and characterization.
J. Virol.
44:720-724[Abstract/Free Full Text].
|
| 8.
|
Craven, R. C.,
R. P. Bennett, and J. W. Wills.
1991.
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly.
J. Virol.
65:6205-6217[Abstract/Free Full Text].
|
| 9.
|
Dettenhofer, M., and X.-F. Yu.
1999.
Highly purified human immunodeficiency virus type I reveals a virtual absence of Vif in virions.
J. Virol.
73:1460-1467[Abstract/Free Full Text].
|
| 10.
|
Enssle, J.,
N. Fischer,
A. Moebes,
B. Mauer,
U. Smola, and A. Rethwilm.
1997.
Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle.
J. Virol.
71:7312-7317[Abstract].
|
| 11.
|
Enssle, J.,
I. Jordan,
B. Mauer, and A. Rethwilm.
1996.
Foamy virus reverse transcriptase is expressed independently from the Gag protein.
Proc. Natl. Acad. Sci. USA
93:4137-4141[Abstract/Free Full Text].
|
| 12.
|
Erlwein, O.,
P. D. Bieniasz, and M. O. McClure.
1998.
Sequences in pol are required for transfer of human foamy virus-based vectors.
J. Virol.
72:5510-5516[Abstract/Free Full Text].
|
| 13.
|
Flügel, R. M.
1991.
Spumaviruses: a group of complex retroviruses.
J. Acquired Immune Defic. Syndr. Hum. Retrovirol.
4:739-750.
|
| 14.
|
Hatfield, D. L.,
J. G. Levin,
A. Rein, and S. Oroszlan.
1992.
Translation suppression in retroviral gene expression.
Adv. Virus Res.
41:193-239[Medline].
|
| 15.
|
Heinkelein, M.,
M. Schmidt,
N. Fischer,
A. Moebes,
D. Lindemann,
J. Enssle, and A. Rethwilm.
1998.
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors.
J. Virol.
72:6307-6314[Abstract/Free Full Text].
|
| 16.
|
Hu, J., and C. Seeger.
1996.
Expression and characterization of hepadnavirus reverse transcriptases.
Methods Enzymol.
275:195-208[Medline].
|
| 17.
|
Hu, J., and C. Seeger.
1996.
Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase.
Proc. Natl. Acad. Sci. USA
93:1060-1064[Abstract/Free Full Text].
|
| 18.
|
Hu, J.,
D. O. Toft, and C. Seeger.
1997.
Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids.
EMBO J.
16:59-68[Medline].
|
| 19.
|
Hu, S. C.,
D. L. Court,
M. Zweig, and J. G. Levin.
1986.
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli.
J. Virol.
60:267-274[Abstract/Free Full Text].
|
| 20.
|
Hwang, W. L., and T. S. Su.
1998.
Translational regulation of hepatitis B virus polymerase gene by termination-reinitiation of an upstream minicistron in a length-dependent manner.
J. Gen. Virol.
79:2181-2189[Abstract].
|
| 21.
|
Jacks, T.
1990.
Translational suppression in gene expression in retroviruses and retrotransposons, p. 93-124.
In
R. Swanstrom, and P. K. Vogt (ed.), Retroviruses; strategies of replication, 1st ed. Springer-Verlag, Berlin, Germany.
|
| 22.
|
Karacostas, V.,
E. J. Wolffe,
K. Nagashima,
M. A. Gonda, and B. Moss.
1993.
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
Virology
193:661-671[Medline].
|
| 23.
|
Kögel, D.,
M. Aboud, and R. M. Flügel.
1995.
Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains.
Virology
213:97-108[Medline].
|
| 24.
|
Kögel, D.,
M. Aboud, and R. M. Flügel.
1995.
Mutational analysis of the reverse transcriptase and ribonuclease H domains of the human foamy virus.
Nucleic Acids Res.
23:2621-2625[Abstract/Free Full Text].
|
| 25.
|
Konvalinka, J.,
M. Löchelt,
H. Zentgraf,
R. M. Flügel, and H. G. Kräusslich.
1995.
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.
J. Virol.
69:7264-7268[Abstract].
|
| 26.
|
Liu, W. T.,
T. Natori,
K. S. Chang, and A. M. Wu.
1977.
Reverse transcriptase of foamy virus. Purification of the enzymes and immunological identification.
Arch. Virol.
55:187-200[Medline].
|
| 27.
|
Löchelt, M., and R. M. Flügel.
1996.
The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein.
J. Virol.
70:1033-1040[Abstract].
|
| 28.
|
Moebes, A.,
J. Enssle,
P. D. Bieniasz,
M. Heinkelein,
D. Lindemann,
M. Bock,
M. O. McClure, and A. Rethwilm.
1997.
Human foamy virus reverse transcription that occurs late in the viral replication cycle.
J. Virol.
71:7305-7311[Abstract].
|
| 29.
|
Parks, W. P.,
G. J. Todaro,
E. M. Scolnick, and S. A. Aaronson.
1971.
RNA dependent DNA polymerase in primate syncytium-forming (foamy) viruses.
Nature
229:258-260[Medline].
|
| 30.
|
Pfrepper, K. I.,
H. R. Rackwitz,
M. Schnölzer,
H. Heid,
M. Löchelt, and R. M. Flügel.
1998.
Molecular characterization of proteolytic processing of the Pol proteins of human foamy virus reveals novel features of the viral protease.
J. Virol.
72:7648-7652[Abstract/Free Full Text].
|
| 31.
|
Pollack, J. R., and D. Ganem.
1993.
An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation.
J. Virol.
67:3254-3263[Abstract/Free Full Text].
|
| 32.
|
Pollack, J. R., and D. Ganem.
1994.
Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis.
J. Virol.
68:5579-5587[Abstract/Free Full Text].
|
| 33.
|
Rethwilm, A.,
G. Darai,
A. Rosen,
B. Maurer, and R. M. Flügel.
1987.
Molecular cloning of the genome of human spumaretrovirus.
Gene
59:19-28[Medline].
|
| 34.
|
Stewart, L., and V. M. Vogt.
1991.
trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase.
J. Virol.
65:6218-6231[Abstract/Free Full Text].
|
| 35.
|
Swanstrom, R., and J. W. Wills.
1997.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. Coffin, S. Hughes, and H. Varmus (ed.), Retroviruses, 1st ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 36.
|
Vogt, V. M., and M. N. Simon.
1999.
Mass determination of Rous sarcoma virus virions by scanning transmission electron microscopy.
J. Virol.
73:7050-7055[Abstract/Free Full Text].
|
| 37.
|
Wang, G. H., and C. Seeger.
1993.
Novel mechanism for reverse transcription in hepatitis B viruses.
J. Virol.
67:6507-6512[Abstract/Free Full Text].
|
| 38.
|
Whitehorn, E. A.,
E. Tate,
S. D. Yanofsky,
L. Kochersperger,
A. Davis,
R. B. Mortensen,
S. Yonkovich,
K. Bell,
B. Dower, and R. W. Barrett.
1995.
A generic method for expression and use of "tagged" soluble versions of cell surface receptors.
Bio/Technology
13:1215-1219[Medline].
|
| 39.
|
Wu, X.,
H. Liu,
H. Xiao,
J. A. Conway,
E. Hehl,
G. V. Kalpana,
V. Prasad, and J. C. Kappes.
1999.
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.
J. Virol.
73:2126-2135[Abstract/Free Full Text].
|
| 40.
|
Yu, S. F.,
D. N. Baldwin,
S. R. Gwynn,
S. Yendapalli, and M. L. Linial.
1996.
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.
Science
271:1579-1582[Abstract].
|
| 41.
|
Yu, S. F., and M. L. Linial.
1993.
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.
J. Virol.
67:6618-6624[Abstract/Free Full Text].
|
| 42.
|
Yu, S. F.,
M. D. Sullivan, and M. L. Linial.
1999.
Evidence that the foamy virus genome is DNA.
J. Virol.
73:1565-1672[Abstract/Free Full Text].
|
Journal of Virology, August 1999, p. 6387-6393, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Roy, J., Linial, M. L.
(2007). Role of the Foamy Virus Pol Cleavage Site in Viral Replication. J. Virol.
81: 4956-4962
[Abstract]
[Full Text]
-
Lehmann-Che, J., Giron, M.-L., Delelis, O., Lochelt, M., Bittoun, P., Tobaly-Tapiero, J., de The, H., Saib, A.
(2005). Protease-Dependent Uncoating of a Complex Retrovirus. J. Virol.
79: 9244-9253
[Abstract]
[Full Text]
-
Peters, K., Wiktorowicz, T., Heinkelein, M., Rethwilm, A.
(2005). RNA and Protein Requirements for Incorporation of the Pol Protein into Foamy Virus Particles. J. Virol.
79: 7005-7013
[Abstract]
[Full Text]
-
Boyer, P. L., Stenbak, C. R., Clark, P. K., Linial, M. L., Hughes, S. H.
(2004). Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase. J. Virol.
78: 6112-6121
[Abstract]
[Full Text]
-
Shaw, K. L., Lindemann, D., Mulligan, M. J., Goepfert, P. A.
(2003). Foamy Virus Envelope Glycoprotein Is Sufficient for Particle Budding and Release. J. Virol.
77: 2338-2348
[Abstract]
[Full Text]
-
Heinkelein, M., Leurs, C., Rammling, M., Peters, K., Hanenberg, H., Rethwilm, A.
(2002). Pregenomic RNA Is Required for Efficient Incorporation of Pol Polyprotein into Foamy Virus Capsids. J. Virol.
76: 10069-10073
[Abstract]
[Full Text]
-
Rinke, C. S., Boyer, P. L., Sullivan, M. D., Hughes, S. H., Linial, M. L.
(2002). Mutation of the Catalytic Domain of the Foamy Virus Reverse Transcriptase Leads to Loss of Processivity and Infectivity. J. Virol.
76: 7560-7570
[Abstract]
[Full Text]
-
Eastman, S. W., Linial, M. L.
(2001). Identification of a Conserved Residue of Foamy Virus Gag Required for Intracellular Capsid Assembly. J. Virol.
75: 6857-6864
[Abstract]
[Full Text]
-
Meiering, C. D., Rubio, C., May, C., Linial, M. L.
(2001). Cell-Type-Specific Regulation of the Two Foamy Virus Promoters. J. Virol.
75: 6547-6557
[Abstract]
[Full Text]
-
Lindemann, D., Pietschmann, T., Picard-Maureau, M., Berg, A., Heinkelein, M., Thurow, J., Knaus, P., Zentgraf, H., Rethwilm, A.
(2001). A Particle-Associated Glycoprotein Signal Peptide Essential for Virus Maturation and Infectivity. J. Virol.
75: 5762-5771
[Abstract]
[Full Text]
-
Tobaly-Tapiero, J., Bittoun, P., Giron, M.-L., Neves, M., Koken, M., Saïb, A., de Thé, H.
(2001). Human Foamy Virus Capsid Formation Requires an Interaction Domain in the N Terminus of Gag. J. Virol.
75: 4367-4375
[Abstract]
[Full Text]
-
Heinkelein, M., Thurow, J., Dressler, M., Imrich, H., Neumann-Haefelin, D., McClure, M. O., Rethwilm, A.
(2000). Complex Effects of Deletions in the 5' Untranslated Region of Primate Foamy Virus on Viral Gene Expression and RNA Packaging. J. Virol.
74: 3141-3148
[Abstract]
[Full Text]